{"id":65658,"date":"2026-05-19T19:44:17","date_gmt":"2026-05-19T11:44:17","guid":{"rendered":"https:\/\/flcube.com\/?p=65658"},"modified":"2026-05-19T19:44:18","modified_gmt":"2026-05-19T11:44:18","slug":"gsks-arexvy-rsv-vaccine-receives-expanded-japanese-approval-for-adults-18-49-at-increased-risk","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=65658","title":{"rendered":"GSK&#8217;s Arexvy RSV Vaccine Receives Expanded Japanese Approval for Adults 18-49 at Increased Risk"},"content":{"rendered":"\n<p><strong>GlaxoSmithKline plc (GSK)<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/GSK:NYSE\">NYSE: GSK<\/a>) announced that Japan&#8217;s <strong>Ministry of Health, Labour and Welfare (MHLW)<\/strong> has <strong>expanded the eligible population<\/strong> for <strong>Arexvy<\/strong> (respiratory syncytial virus vaccine, adjuvanted recombinant) to include <strong>adults aged 18 to 49 years at increased risk (AIR) for RSV disease<\/strong>. This approval significantly broadens market access beyond the vaccine&#8217;s previous indications for adults aged <strong>60+ years<\/strong> and <strong>50-59 AIR<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-expansion-timeline\">Regulatory Expansion Timeline<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Previous Indications<\/th><th>New Indication<\/th><\/tr><\/thead><tbody><tr><td><strong>Adults \u226560 years<\/strong>: All adults for RSV disease prevention<\/td><td><strong>Adults 18-49 years<\/strong>: At increased risk (AIR) for RSV disease<\/td><\/tr><tr><td><strong>Adults 50-59 years<\/strong>: At increased risk (AIR) only<\/td><td><strong>Total eligible population<\/strong>: Now spans ages 18-49 AIR + 50-59 AIR + 60+ all adults<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-evidence-supporting-expansion\">Clinical Evidence Supporting Expansion<\/h2>\n\n\n\n<p>The MHLW approval was supported by data from a <strong>Phase 3b clinical trial (NCT06389487)<\/strong> with compelling immunogenicity results:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Primary Endpoint<\/strong>: Demonstrated <strong>non-inferior immune response<\/strong> in adults aged <strong>18-49 years AIR<\/strong> compared to adults aged <strong>60 years and above<\/strong><\/li>\n\n\n\n<li><strong>Safety Profile<\/strong>: Remained <strong>consistent with previously reported data<\/strong>, with no new safety signals identified<\/li>\n\n\n\n<li><strong>Trial Design<\/strong>: Randomized, controlled study evaluating immunogenicity and safety in younger high-risk populations<\/li>\n\n\n\n<li><strong>Regulatory Strategy<\/strong>: Leveraged established efficacy data from older adult populations while demonstrating comparable immune responses in younger cohorts<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-commercial-implications\">Market Impact &amp; Commercial Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Addressable Population Expansion<\/strong>: The approval potentially adds <strong>millions of additional eligible patients<\/strong> in Japan&#8217;s healthcare system, particularly those with underlying conditions such as chronic respiratory disease, cardiovascular disease, or immunocompromised states<\/li>\n\n\n\n<li><strong>Revenue Catalyst<\/strong>: Analysts estimate this expansion could contribute <strong>\u00a58-12 billion<\/strong> (approximately <strong>$55-80 million<\/strong>) in incremental annual revenue by 2028<\/li>\n\n\n\n<li><strong>Competitive Positioning<\/strong>: Strengthens GSK&#8217;s lead over <strong>Pfizer&#8217;s Abrysvo<\/strong> in the Japanese RSV market, which currently maintains narrower age indications<\/li>\n\n\n\n<li><strong>Global Regulatory Momentum<\/strong>: Japan&#8217;s approval may influence regulatory decisions in other Asia-Pacific markets considering similar label expansions<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-context-in-rsv-vaccination-landscape\">Strategic Context in RSV Vaccination Landscape<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>RSV Disease Burden<\/strong>: Respiratory syncytial virus causes an estimated <strong>33 million lower respiratory tract infections annually<\/strong> in adults globally, with significant morbidity in high-risk populations across all age groups<\/li>\n\n\n\n<li><strong>Vaccination Gap<\/strong>: Prior to recent approvals, no RSV vaccines were available for adults, creating substantial unmet medical need<\/li>\n\n\n\n<li><strong>GSK&#8217;s Portfolio Leadership<\/strong>: Arexvy represents GSK&#8217;s flagship RSV asset, generating <strong>\u00a31.2 billion<\/strong> in 2025 sales and establishing the company as the market leader in adult RSV prevention<\/li>\n\n\n\n<li><strong>Japan Healthcare Integration<\/strong>: The expanded indication aligns with Japan&#8217;s proactive approach to preventive healthcare and vaccination programs for high-risk populations<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-dynamics\">Competitive Dynamics<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Direct Competitor<\/strong>: Pfizer&#8217;s <strong>Abrysvo<\/strong> currently approved in Japan for adults <strong>60+ years<\/strong> only, without expanded AIR indications for younger adults<\/li>\n\n\n\n<li><strong>Differentiation Advantage<\/strong>: GSK&#8217;s broader label provides prescribing flexibility and captures a larger patient population<\/li>\n\n\n\n<li><strong>Pricing Strategy<\/strong>: Premium pricing maintained across all age groups, reflecting the significant clinical benefit and unmet need<\/li>\n\n\n\n<li><strong>Market Access<\/strong>: Strong relationships with Japanese healthcare providers and payers facilitate rapid adoption of expanded indications<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory approvals, market opportunities, and commercial expectations for Arexvy. Actual results may differ due to risks including competitive dynamics, market adoption rates, pricing pressures, and regulatory developments in other jurisdictions.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>GlaxoSmithKline plc (GSK) (NYSE: GSK) announced that Japan&#8217;s Ministry of Health, Labour and Welfare (MHLW)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":65660,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[278,184,914,15,12],"class_list":["post-65658","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-glaxosmithkline","tag-gsk","tag-nyse-gsk","tag-product-approvals","tag-vaccine"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>GSK&#039;s Arexvy RSV Vaccine Receives Expanded Japanese Approval for Adults 18-49 at Increased Risk - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"GlaxoSmithKline plc (GSK) (NYSE: GSK) announced that Japan&#039;s Ministry of Health, Labour and Welfare (MHLW) has expanded the eligible population for Arexvy (respiratory syncytial virus vaccine, adjuvanted recombinant) to include adults aged 18 to 49 years at increased risk (AIR) for RSV disease. This approval significantly broadens market access beyond the vaccine&#039;s previous indications for adults aged 60+ years and 50-59 AIR.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=65658\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GSK&#039;s Arexvy RSV Vaccine Receives Expanded Japanese Approval for Adults 18-49 at Increased Risk\" \/>\n<meta property=\"og:description\" content=\"GlaxoSmithKline plc (GSK) (NYSE: GSK) announced that Japan&#039;s Ministry of Health, Labour and Welfare (MHLW) has expanded the eligible population for Arexvy (respiratory syncytial virus vaccine, adjuvanted recombinant) to include adults aged 18 to 49 years at increased risk (AIR) for RSV disease. This approval significantly broadens market access beyond the vaccine&#039;s previous indications for adults aged 60+ years and 50-59 AIR.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=65658\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-19T11:44:17+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-19T11:44:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1902.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65658#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65658\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"GSK&#8217;s Arexvy RSV Vaccine Receives Expanded Japanese Approval for Adults 18-49 at Increased Risk\",\"datePublished\":\"2026-05-19T11:44:17+00:00\",\"dateModified\":\"2026-05-19T11:44:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65658\"},\"wordCount\":513,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65658#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/1902.webp\",\"keywords\":[\"GlaxoSmithKline\",\"GSK\",\"NYSE: GSK\",\"Product approvals\",\"Vaccine\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65658#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65658\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=65658\",\"name\":\"GSK's Arexvy RSV Vaccine Receives Expanded Japanese Approval for Adults 18-49 at Increased Risk - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65658#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65658#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/1902.webp\",\"datePublished\":\"2026-05-19T11:44:17+00:00\",\"dateModified\":\"2026-05-19T11:44:18+00:00\",\"description\":\"GlaxoSmithKline plc (GSK) (NYSE: GSK) announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has expanded the eligible population for Arexvy (respiratory syncytial virus vaccine, adjuvanted recombinant) to include adults aged 18 to 49 years at increased risk (AIR) for RSV disease. This approval significantly broadens market access beyond the vaccine's previous indications for adults aged 60+ years and 50-59 AIR.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65658#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65658\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65658#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/1902.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/1902.webp\",\"width\":1080,\"height\":608,\"caption\":\"GSK's Arexvy RSV Vaccine Receives Expanded Japanese Approval for Adults 18-49 at Increased Risk\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65658#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GSK&#8217;s Arexvy RSV Vaccine Receives Expanded Japanese Approval for Adults 18-49 at Increased Risk\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"GSK's Arexvy RSV Vaccine Receives Expanded Japanese Approval for Adults 18-49 at Increased Risk - Insight, China&#039;s Pharmaceutical Industry","description":"GlaxoSmithKline plc (GSK) (NYSE: GSK) announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has expanded the eligible population for Arexvy (respiratory syncytial virus vaccine, adjuvanted recombinant) to include adults aged 18 to 49 years at increased risk (AIR) for RSV disease. This approval significantly broadens market access beyond the vaccine's previous indications for adults aged 60+ years and 50-59 AIR.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=65658","og_locale":"en_US","og_type":"article","og_title":"GSK's Arexvy RSV Vaccine Receives Expanded Japanese Approval for Adults 18-49 at Increased Risk","og_description":"GlaxoSmithKline plc (GSK) (NYSE: GSK) announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has expanded the eligible population for Arexvy (respiratory syncytial virus vaccine, adjuvanted recombinant) to include adults aged 18 to 49 years at increased risk (AIR) for RSV disease. This approval significantly broadens market access beyond the vaccine's previous indications for adults aged 60+ years and 50-59 AIR.","og_url":"https:\/\/flcube.com\/?p=65658","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-19T11:44:17+00:00","article_modified_time":"2026-05-19T11:44:18+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1902.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=65658#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=65658"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"GSK&#8217;s Arexvy RSV Vaccine Receives Expanded Japanese Approval for Adults 18-49 at Increased Risk","datePublished":"2026-05-19T11:44:17+00:00","dateModified":"2026-05-19T11:44:18+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=65658"},"wordCount":513,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=65658#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1902.webp","keywords":["GlaxoSmithKline","GSK","NYSE: GSK","Product approvals","Vaccine"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=65658#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=65658","url":"https:\/\/flcube.com\/?p=65658","name":"GSK's Arexvy RSV Vaccine Receives Expanded Japanese Approval for Adults 18-49 at Increased Risk - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=65658#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=65658#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1902.webp","datePublished":"2026-05-19T11:44:17+00:00","dateModified":"2026-05-19T11:44:18+00:00","description":"GlaxoSmithKline plc (GSK) (NYSE: GSK) announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has expanded the eligible population for Arexvy (respiratory syncytial virus vaccine, adjuvanted recombinant) to include adults aged 18 to 49 years at increased risk (AIR) for RSV disease. This approval significantly broadens market access beyond the vaccine's previous indications for adults aged 60+ years and 50-59 AIR.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=65658#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=65658"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=65658#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1902.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1902.webp","width":1080,"height":608,"caption":"GSK's Arexvy RSV Vaccine Receives Expanded Japanese Approval for Adults 18-49 at Increased Risk"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=65658#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"GSK&#8217;s Arexvy RSV Vaccine Receives Expanded Japanese Approval for Adults 18-49 at Increased Risk"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1902.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65658","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=65658"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65658\/revisions"}],"predecessor-version":[{"id":65661,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65658\/revisions\/65661"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/65660"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=65658"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=65658"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=65658"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}